Sareum Holdings — New collaboration cements focus on CNS
Sareum has announced a strategic collaboration with Receptor.AI, a ‘techbio’ company harnessing generative AI to accelerate drug discovery across a...
174 Views
Hybridan Research: Sareum Holdings plc: Significant Stepping Stone
The toxicology studies program for its lead TYK2/JAK1 inhibitor, SDC-1801, are starting. In 2024, SDC-1801 which is a dual inhibitor targeting...
338 Views
Sareum Holdings — A decisive step towards Phase II
Sareum Holdings has reported the initiation of toxicology studies required ahead of the Phase II studies for its lead TYK2/JAK1 asset, SDC-1801. We...
239 Views
Hybridan Research: Sareum Holdings plc
Progress is reported on Sareum’s most advanced assets which are the foundation of its near-term clinical strategy and development priorities. The...
286 Views
Sareum Holdings — Broader pipeline, bigger milestones
Sareum Holdings’ H125 results (to 31 December 2024) summarised a period of operational progress and an improved capital position, with successful...
266 Views